Idexx Laboratories, Inc. IDXX

NAS: IDXX | ISIN: US45168D1046   1/07/2025
542,65 USD (+1,18%)
(+1,18%)   1/07/2025
Grafiek Idexx Laboratories, Inc. Grafiek Idexx Laboratories, Inc.

Idexx Laboratories, Inc. in het nieuws

30 juli 2024 · IDEXX Releases 2023 Corporate Responsibility Report, Highlighting Progress Against Its Goals · Persbericht

6 juni 2024 · IDEXX annonce un analyseur cellulaire révolutionnaire sans préparation de lames, IDEXX inVue Dx™, qui simplifie votre flux de travail à la clinique · Persbericht

4 juni 2024 · IDEXX Expands Test Menu for the Catalyst Platform to Support Veterinarians Globally in Diagnosing Pancreatitis · Persbericht

15 februari 2024 · IDEXX Launches Vello™, an Innovative Pet Owner Engagement Software Solution, Streamlining How Practices and Clients Connect · Persbericht

12 januari 2024 · IDEXX Expands Fecal Dx® Antigen Testing Platform with Cystoisospora Detection, Marking the Second Platform Expansion in Less than Two Years · Persbericht

12 januari 2024 · IDEXX Announces Revolutionary Slide-Free Cellular Analyzer, IDEXX inVue Dx™ Transforming In-Clinic Workflows · Persbericht

8 november 2023 · IDEXX Expands SNAP Platform with Leish 4Dx Test to Support Veterinarians Globally in Diagnosing Vector-borne Diseases · Persbericht

25 juli 2023 · IDEXX Releases 2022 Corporate Responsibility Report, Providing Environmental, Social, and Governance Updates · Persbericht

15 juni 2023 · IDEXX Announces Novel Diagnostic Test for Kidney Injury, Expanding the Veterinary Industry's Most Comprehensive Renal Testing Portfolio · Persbericht

21 februari 2023 · IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences · Persbericht

Profiel Idexx Laboratories, Inc.

Gezondheidstechnologie
Medische Specialiteiten
Productie
Productie van medische instrumenten

Website: www.idexx.com

Hoofdzetel: Westbrook, Maine vlag Verenigde Staten

CEO: Jonathan Jay Mazelsky

Werknemers: 7.962

Mijn selecties